Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1, either as monotherapy or in combination with angiogenesis inhibitors, have become the standard of care for metastatic ccRCC in recent years.2 The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.